Drug intelligence / Profile preview

AR11

Development stage: Unknown
Administration: Oral

Overview

AR11 is an investigational drug that has been evaluated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 12 years. It was studied in a dose-optimized, randomized, double-blind, placebo-controlled crossover study to assess its efficacy in a laboratory classroom setting utilizing SKAMP and PERMP assessments. The specific mechanism of action for this drug is not detailed in the provided clinical trial information.

Targets

CYP19A1 (Aromatase)

Beyond the preview

Go deeper on AR11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR11.

Explore the full profile